Share
Andre Hoekema
Curve Therapeutics, a biotech company revolutionizing drug discovery with its proprietary intracellular screening platform, announced the appointment of Dr. Andre Hoekema as Chair of the Board, along with Cora Griffin as Head of Business Development. These leadership additions follow the recent appointment of Simon Jones as CFO/COO, signaling the company’s ongoing growth and strategic momentum.
Dr. Hoekema brings 40 years of biotech industry expertise, having served as Chief Business Officer at Galapagos Pharma for 18 years, where he played a pivotal role in leading partnerships, mergers, acquisitions, and successful IPOs on Euronext and Nasdaq. Cora Griffin, an experienced business development professional, joins Curve after her key role in Pfizer's acquisition of ReViral for US$525 million.
CEO Simon Kerry expressed his confidence in the new leadership, emphasizing their experience and vision to accelerate Curve’s proprietary Microcycle discovery platform and advance its therapeutic pipeline toward clinical development.
Dr. Hoekema shared his excitement about joining Curve at this pivotal time, stating that the company's innovative approach and ambition to transform drug discovery through strategic partnerships position it for significant growth.
